Company Profile
PAVmed Stock Price, News & Catalysts
- Ticker:
- PAVM
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
5.33 USD (+2.40%)
Close
Last updated: August 17, 2026
43M USD
Market cap
Why the stock is moving
Following the latest company update, “PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results”, PAVM closed up 9.70% at $5.20 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Diversified Medical Technology Portfolio
PAVmed is a diversified commercial-stage medical technology company with businesses spanning diagnostic testing, digital health, and implantable medical devices. It develops products through both majority-owned subsidiaries and internally managed device programs.
Lucid Esophageal Diagnostics
Lucid Diagnostics commercializes the EsoGuard DNA test and EsoCheck cell-collection device for detecting esophageal precancer associated with gastroesophageal reflux disease. The platform is designed to identify at-risk patients before progression to esophageal adenocarcinoma.
Veris Cancer Monitoring
Veris Health is developing a digital oncology platform for remote monitoring of patients receiving cancer treatment. Its implantable physiologic monitor is intended to be placed during chemotherapy-port implantation and provide continuous data that may support earlier detection of treatment complications.
PortIO
PortIO is an implantable intraosseous vascular-access device intended to provide long-term access through bone rather than conventional veins. Early clinical work has evaluated device patency and usability as PAVmed prepares for further regulatory interaction.
Octeris
Octeris is a multimodal endoscopic imaging probe designed to provide real-time tissue characterization during endoscopic procedures. PAVmed is preparing a clinical validation study with the University of North Carolina to assess the technology in a clinical setting.
Future catalysts
- Submission of an FDA pre-submission meeting request for PortIO in Q4 2026.
- FDA 510(k) submission for the Veris implantable physiologic monitor in early 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PAVmed (PAVM)?
PAVmed (PAVM) most recently closed at 5.33 USD, a +2.40% move versus the previous session.
What is the market cap of PAVmed (PAVM)?
PAVmed currently has a market capitalization of 43M USD on BioPharmSignal.
What does PAVmed do?
Diversified Medical Technology Portfolio PAVmed is a diversified commercial-stage medical technology company with businesses spanning diagnostic testing, digital health, and implantable medical devices. It develops products through both majority-owned subsidiaries and internally managed device programs. Lucid Esophageal Diagnostics Lucid Diagnostics...
On which exchange is PAVM stock listed?
PAVmed (PAVM) is associated with NASDAQ, United States, MedTech.
What is Diversified?
Diversified Medical Technology Portfolio PAVmed is a diversified commercial-stage medical technology company with businesses spanning diagnostic testing, digital health, and implantable medical devices.
Which conditions is PAVmed targeting with Diversified?
PAVmed is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does PAVmed describe recent progress with Diversified?
Submission of an FDA pre-submission meeting request for PortIO in Q4 2026. FDA 510(k) submission for the Veris implantable physiologic monitor in early 2027.
What is Medical?
Diversified Medical Technology Portfolio PAVmed is a diversified commercial-stage medical technology company with businesses spanning diagnostic testing, digital health, and implantable medical devices.